Carvedilol controlled release - GlaxoSmithKline

Drug Profile

Carvedilol controlled release - GlaxoSmithKline

Alternative Names: Carvedilol phosphate; Coreg CR; Coreg CR Micropump; COREG MR; SKF 105517-D

Latest Information Update: 09 Jan 2017

Price : $50

At a glance

  • Originator Roche
  • Developer Columbia University; GlaxoSmithKline
  • Class Antihypertensives; Carbazoles; Ethanolamines; Heart failure therapies; Ischaemic heart disorder therapies; Phenyl ethers; Propanolamines; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Beta-adrenergic receptor antagonists; Calcium channel antagonists; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Heart failure; Hypertension; Left ventricular dysfunction
  • Discontinued Epilepsy

Most Recent Events

  • 03 Jan 2017 Flamel Technologies completed its cross-border merger with Avadel Pharmaceuticals and is now called Avadel Pharmaceuticals
  • 10 Apr 2015 Discontinued - Phase-II/III for Epilepsy (Adjunctive treatment) in USA (PO) (NCT00524134)
  • 30 May 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top